摘要
目的:探讨术前艾迪注射液联合新辅助化疗用于治疗非小细胞肺癌(NSCLC)的疗效。方法:选取NSCLC患者55例,根据在新辅助化疗时是否联合使用艾迪注射液分为对照组与治疗组,对照组未使用艾迪注射液,共20例,治疗组使用艾迪注射液,共35例。观察两组患者近期疗效、手术时间、出血量、切除率以及毒副反应,并通过流式细胞术检测治疗前后患者外周血CD4+CD25+调节性T细胞数量。结果:与对照组相比,治疗组患者手术出血量显著下降(P<0.05),分别为(615.49±114.08)mL与(530.15±104.55)mL;治疗总有效率显著上升(P<0.05),分别为30.00%,45.71%;白细胞减少发生率显著下降(P<0.05),分别为60.00%,37.14%;与治疗前相比,所有患者外周血CD4+CD25+调节性T细胞显著降低(P<0.05),以治疗组患者降低更加明显(P<0.05)。结论:艾迪注射液联合新辅助化疗可提高NSCLC的治疗效果,提高肿瘤免疫,减少不良反应。
Objective：To explore effect of combination of Aidi injection and neoadjuvant chemotherapy on patients with non-small-cell lung cancer and number of CD4＋CD25＋ T regulatory cells（NSCLC）.Method：Fifty patients with NSCLC were chosen for this research.Patients were divided into control group of 20 patients without application of Aidi injection and treatment group of 35 patients applied with Aidi injection.The following indexes like their short-term curative effect,operation time,blood loss in operations,ablation rate and side effects were observed;flow cytometry was used to detect and compare number of Treg before and after treatments.Result：Compared with control group,blood loss in operation was decreased significantly（615.49±114.08）mL vs.（530.15±104.55）mL（P〈0.05）,curative effect increased significantly（30.00% vs 45.71%）（P〈0.05）,and occurrence of leucopenia decreased significantly（60.00% vs 37.14%）（P〈0.05）.Number of Treg was decreased significantly after treatments for all patients（P〈0.05）,which was more significant in treatment group than in control group（P〈0.05）.Conclusion：Combination of Aidi injection and neoadjuvant chemotherapy can enhance clinical effects on patients with NSCLC,meanwhile enhance tumor immunity and reduce side effect during the treatment.
出处
《中国实验方剂学杂志》
CAS
北大核心
2012年第18期291-294,共4页
Chinese Journal of Experimental Traditional Medical Formulae
关键词
艾迪注射液
新辅助化疗
非小细胞肺癌
肿瘤免疫
Aidi injection； neoadjuvant chemotherapy； non-small-cell lung cancer； tumor immunity
